Alzheimer's Clinical Trials Consortium

Alzheimer's Clinical Trials Consortium
Name	Alzheimer's Clinical Trials Consortium
Formation	2018
Type	Consortium
Headquarters	United States
Region served	International
Leader title	Director

Alzheimer's Clinical Trials Consortium

The Alzheimer's Clinical Trials Consortium is a networked research collaboration focused on accelerating therapeutic development for Alzheimer's disease through coordinated clinical trials, standardized protocols, and shared infrastructure. It operates across multiple academic medical centers and engages with regulatory agencies, industry partners, and advocacy organizations to run multi-site studies testing pharmacologic and non-pharmacologic interventions. The consortium emphasizes scalable trial designs, biomarker validation, and harmonized data collection to improve trial efficiency and reproducibility.

Overview

The consortium brings together investigators from leading institutions such as Johns Hopkins University, Harvard Medical School, Massachusetts General Hospital, University of California, San Francisco, Mayo Clinic, University of Pennsylvania, and Columbia University Irving Medical Center to implement phase II and phase III studies. Its activities intersect with initiatives from National Institutes of Health, National Institute on Aging, Food and Drug Administration, European Medicines Agency, Alzheimer’s Association, and clinical networks like ClinicalTrials.gov, Observational Health Data Sciences and Informatics, and The Global Alzheimer's Platform Foundation. The consortium collaborates with pharmaceutical companies including Eli Lilly and Company, Biogen, Roche, Novartis, AstraZeneca, Pfizer, Johnson & Johnson, Merck & Co., Sanofi, and GlaxoSmithKline.

History and Formation

Established in the late 2010s, the consortium was formed amid growing demands for coordinated multicenter trials following landmark studies led by investigators associated with Washington University in St. Louis, University of California, Los Angeles, University of Wisconsin–Madison, Duke University, Yale School of Medicine, University of Michigan, and Northwestern University Feinberg School of Medicine. Its formation was influenced by trial designs and networks developed by groups at Mount Sinai Health System, University of Cambridge, Karolinska Institutet, University College London, and McGill University Health Centre. Founding leaders included clinician-scientists who had worked with programs at Rush University Medical Center, Brigham and Women's Hospital, Weill Cornell Medicine, and University of Toronto.

Organization and Governance

Governance typically involves steering committees, scientific advisory boards, and site principal investigators drawn from institutions such as Stanford University School of Medicine, University of California, San Diego, Emory University School of Medicine, University of Pittsburgh Medical Center, Cleveland Clinic, Vanderbilt University Medical Center, University of Colorado Anschutz Medical Campus, University of Texas Southwestern Medical Center, and Rice University. Regulatory affairs and ethics oversight engages experts connected to World Health Organization, Centers for Disease Control and Prevention, European Union Agency for Fundamental Rights, and bioethics groups at Georgetown University. Data safety monitoring boards include members affiliated with New York University Langone Health, Indiana University School of Medicine, University of British Columbia, and Monash University.

Research Programs and Clinical Trials

The consortium runs programs spanning disease-modifying therapies, symptomatic treatments, prevention trials, and biomarker development; trial portfolios include monoclonal antibodies, small molecules, immunotherapies, and lifestyle interventions tested across cohorts recruited from registries like Alzheimer's Disease Neuroimaging Initiative, UK Biobank, All of Us Research Program, Framingham Heart Study, Baltimore Longitudinal Study of Aging, and The 90+ Study. Trials employ imaging and fluid biomarkers standardized with centers such as Banner Alzheimer's Institute, The Rockefeller University, Scripps Research Institute, Cold Spring Harbor Laboratory, and The Broad Institute of MIT and Harvard. Adaptive platform trials within the consortium draw on methodologies developed in programs connected to REMAP-CAP, I-SPY, and Platform Trial Working Group contributors from Oxford University and Imperial College London.

Collaborations and Partnerships

Partnerships span NGOs, advocacy groups, and multinational pharmaceutical consortia, including collaborations with Alzheimer Europe, Dementia Australia, Canadian Consortium on Neurodegeneration in Aging, European Academy of Neurology, American Neurological Association, Society for Neuroscience, and International Conference on Alzheimer's and Parkinson's Diseases. Academic partnerships extend to University of Melbourne, University of Sydney, University of Tokyo, Peking University Health Science Center, Seoul National University, King's College London, Leiden University Medical Center, Heidelberg University Hospital, Charité – Universitätsmedizin Berlin, and University of São Paulo. The consortium engages with funding agencies including Bill & Melinda Gates Foundation, Alfred P. Sloan Foundation, Robert Wood Johnson Foundation, and governmental research councils like UK Research and Innovation and Canadian Institutes of Health Research.

Impact and Contributions

Contributions include harmonized trial protocols adopted by sites affiliated with Harvard T.H. Chan School of Public Health, Yale School of Public Health, Brown University, Johns Hopkins Bloomberg School of Public Health, and Columbia University Mailman School of Public Health; validated biomarker assays co-developed with laboratories at National Institutes of Health Clinical Center and European Molecular Biology Laboratory; and training programs for investigators modeled after curricula from National Academy of Medicine, Association of American Medical Colleges, and European Scientist Training Course. The consortium's work has informed regulatory guidance referenced by panels at Food and Drug Administration Advisory Committee, academic symposia at Society for Clinical Trials, and policy discussions hosted by G20 health working groups.

Funding and Resources

Funding sources combine federal grants from agencies like National Institutes of Health and National Institute on Aging, philanthropic support from entities such as Alzheimer's Association and Chan Zuckerberg Initiative, and industry-sponsored trial agreements with companies like Eli Lilly and Company and Biogen. In-kind resources and core facilities are provided through partner institutions including Mayo Clinic Alix School of Medicine, Massachusetts General Hospital Research Institute, UC San Diego Health, Scripps Research, and Icahn School of Medicine at Mount Sinai. Shared data repositories and computational resources are hosted in collaboration with Amazon Web Services, Google Cloud Platform, and academic supercomputing centers at Argonne National Laboratory and Lawrence Berkeley National Laboratory.

Category:Medical research organizations